Diabetes therapy : research, treatment and education of diabetes and related disorders

Do Dual Incretin Receptor Drugs Provide Better Heart Protection than Drugs Targeting Only GLP-1 Receptors? Key Findings from SURPASS-CVOT

Updated

Abstract

Essence

Tirzepatide matched dulaglutide for major cardiovascular events but did not prove superior cardiovascular protection in SURPASS-CVOT.

Evidence

This commentary highlights SURPASS-CVOT, an active-comparator cardiovascular outcomes trial in type 2 diabetes where tirzepatide was noninferior to dulaglutide for (HR 0.92; 95.3% CI 0.83-1.01; p = 0.086) despite greater HbA1c and weight reductions.

Caveat

Superiority over dulaglutide was narrowly missed, and exploratory mortality, renal, and imputed-placebo findings require cautious interpretation.

Simplified

Key numbers

28%
Risk Reduction
Risk reduction in from tirzepatide.
0.8%
HbA1c Reduction
Tirzepatide's HbA1c reduction compared to dulaglutide.
7%
Weight Loss
Weight loss achieved with tirzepatide compared to dulaglutide.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

1 of 1
author reports competing interests
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free